(S)-4-ACPBPA

• 分子结构分类: 有机化合物 - 有机磷化合物
• 英文名称: (S)-4-ACPBPA
• 英文别名: [(S)-4-aminocyclopenten-1-yl]butylphosphinic acid；(+)-(S)-4-amino-1-cyclopent-1-enyl(butyl)phosphinic acid；(S)-(4-aminocyclopent-1-enyl)butylphosphinic acid；[(4S)-4-aminocyclopenten-1-yl]-butylphosphinic acid
• 化学式: C₉H₁₈NO₂P
• 分子量: 203.221
• InChiKey: WCUPFODMXRJZNL-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-4-ACPBPA 、 BOC-甘氨酸-N-羟基琥柏酰亚胺酯 在 碳酸氢钠 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 为溶剂， 反应 16.0h， 以82%的产率得到((S)-4-(2-((tert-butoxycarbonyl)amino)acetamido)cyclopent-1-en-1-yl)(butyl)phosphinic acid
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Fluorescent and Biotinylated Antagonists of ρ₁ GABA_C Receptors

  摘要：

  The rho(1) GABA(C) receptor is a ligand-gated chloride ion channel that shows promise as a therapeutic target for myopia, sleep disorders, memory and learning facilitation, and anxiety-related disorders. As such, there is a need for molecular probes to understand the role GABA(C) receptors play in physiological and pathological processes. To date, no labeled (either radioactive or fluorescent) GABA(C) selective ligand has been developed that can act as a marker for GABA(C) receptor visualization and localization studies. Herein, we report a series of fluorescent ligands containing different-sized linkers and fluorophores based around (S)-4-ACPBPA [(4-aminocyclopenten-1-yl)-butylphosphinic acid], a selective GABA(C) antagonist. One of these conjugates, (S)-4-ACPBPA-C5-BODIPY (13), displayed moderate potency (IC50 = 58.61 mu M) and selectivity (>100 times) for rho(1) over alpha(1)beta(2)gamma(2L) GABA(A) receptors. These conjugates are novel lead agents for the development of more potent and selective fluorescent probes for studying the localization and function of GABA(C) receptors in living cells.

  DOI：

  10.1021/ml300476v
• 作为产物：
  描述：

  在 盐酸 作用下， 以 水 为溶剂， 反应 30.0h， 生成 (S)-4-ACPBPA
  参考文献：
  名称：

  Novel γ-Aminobutyric Acid ρ₁Receptor Antagonists; Synthesis, Pharmacological Activity and Structure−Activity Relationships

  摘要：

  gamma-Aminobutyric acid (GABA) analogues based on 4-amino-cyclopent-1-enyl phosphinic acid (34-42) and 3-aminocyclobutane phosphinic acids (51, 52, 56, 57) were investigated in order to obtain selective homomeric rho(1) GABA(C) receptor antagonists. The effect of the stereochemistry and phosphinic acid substituent of these compounds on potency and selectivity within the GABA receptor subtypes was investigated. Compounds of high potency at GABA(C) rho(1) receptors (36, K-B = 0.78 mu M) and selectivity greater than 100 times (41, K-B = 4.97 mu M) were obtained. The data obtained was analyzed along with the known set of GABA(C) rho(1) receptor-ligands, leading to the development of a pharmacophore model for this receptor, which can be used for in silico screening.

  DOI：

  10.1021/jm7015842

文献信息

• Neurologically-Active Compounds
  申请人：Chebib Mary

  公开号：US20080032950A1

  公开（公告）日：2008-02-07

  The invention provides a compound of the formula I: wherein R is methyl, ethyl, propyl, isopropyl, butyl, pentyl, neo-pentyl or cyclohexyl, or a salt or solvate thereof. These compounds are selective GABA C receptor antagonists. The invention also provides pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof. The invention also provides methods of enhancing the cognitive activity of an animal and methods of stimulating memory capacity in an animal, comprising the step of administering to the animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt or solvate thereof.

  本发明提供一种化合物，其化学式为I：其中R为甲基、乙基、丙基、异丙基、丁基、戊基、新戊基或环己基，或其盐或溶剂化物。这些化合物是选择性的GABAC受体拮抗剂。本发明还提供包括化合物I或其药学上可接受的盐或溶剂化物的制药组合物。本发明还提供增强动物认知活动和刺激动物记忆能力的方法，其中包括向动物施用化合物I或其药学上可接受的盐或溶剂化物的有效量。
• NEUROLOGICALLY-ACTIVE COMPOUNDS
  申请人：THE UNIVERSITY OF SYDNEY

  公开号：EP1773740B1

  公开（公告）日：2009-02-18
• METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION
  申请人：Jensen Ralph J.

  公开号：US20150038464A1

  公开（公告）日：2015-02-05

  Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit γ-aminobutyric acid (GABA) signaling to a subject with retinal degeneration. In some embodiments, the methods include selecting a subject with retinal degeneration and administering a γ-aminobutyric acid C (GABA C ) receptor antagonist to the subject. In one example, the GABA C receptor antagonist is (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA). In other embodiments, the methods include selecting a subject with retinal degeneration and administering a metabotropic glutamate receptor (mGluR) antagonist to the subject. In one example, the mGluR antagonist is a mGlu1 receptor antagonist (for example, JNJ16259685).